MariMed Refinances Chicago Atlantic Loan
- MariMed Inc. has closed a $58.7 million secured credit facility with a U.S. chartered bank.
- The debt refinancing will result in a reduction of $4.7 million in principal and interest expense in the first year and $3.5 million annually for the next four years.
- The refinancing deal does not include an equity component, avoiding dilution to the shareholders.
- MariMed plans to use the savings from the refinancing for potential acquisitions and to bolster cash flow from operations.
10-Year Term at Reduced Annualized Interest Rate Will Result in $4.7 Million Reduction to Principal and Interest Expense in the First 12 Months and $3.5 Million Annually for Next Four Years and Includes No Equity Component
NORWOOD, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) — MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, announced that it closed a $58.7 million secured credit facility with a U.S. chartered bank on November 17, 2023.
“I am delighted to announce the closing of this debt refinancing, which will generate significant cash savings,” said Jon Levine, MariMed’s Chief Executive Officer. “Securing a lower rate, when interest rates continue to rise, is the result of the financial discipline we have displayed over the past decade. Importantly, we are pleased there is no warrant or other equity component resulting in dilution to our shareholders.”
By paying off the Chicago Atlantic loan, we were also able to unencumber our operating assets in Illinois, Ohio, and Delaware, as well as our branded products, providing additional levers for future term loans at attractive rates if we choose.
Additionally, the credit facility bolsters our ability to continue executing our strategic plan, particularly as it relates to growing the Company through mergers and acquisitions. There are many attractive opportunities for accretive deals to be made in our industry, and we intend to explore any that will increase shareholder value.
Highlights of the refinancing deal include:
“The principal and interest savings of $4.7 million in the first year, and $3.5 million a year for the four years thereafter, will significantly improve cash flow from operations going forward, and provide funds that can be used for acquisitions if we choose,” said Levine. “Including this facility, our lower blended interest rate1 and new debt facility represent a Debt/EBITDA ratio of 2.5X, which is among the lowest in the cannabis industry and speak to our ability to generate significant positive cash flow from operations.”
¹The blended interest rate is calculated as the weighted average rate of all interest-bearing loans, mortgages, and seller notes.
Advisors and Consultants
Burns & Levinson LLP, Boston, MA (Frank A. Segall) and Kurzman Eisenberg Corbin & Lever, LLP, White Plains, NY (Kenneth S. Rose) represented MariMed in connection with the financing transaction. Mr. Segall, Chair of Burns & Levinson LLP ‘s Cannabis Business & Law Advisory Group, assisted in arranging the transaction.
About MariMed
MariMed Inc., a multi-state cannabis operator, is dedicated to improving lives every day through its high-quality products, its actions, and its values. The Company develops, owns, and manages seed to sale state-licensed cannabis facilities, which are models of excellence in horticultural principles, cannabis cultivation, cannabis-infused products, and dispensary operations. MariMed has an experienced management team that has produced consistent growth and success for the Company and its managed business units. Proprietary formulations created by the Company’s technicians are embedded in its top-selling and award-winning products and brands, including Betty’s Eddies™, Nature’s Heritage™, InHouse, Bubby’s Baked™, K Fusion™, Kalm Fusion™, and Vibations™, which are trademarks of MariMed. For additional information, visit www.marimedinc.com.
Original press release